早期非小细胞肺癌术后辅助化疗生存获益分析

doi:10.3969/j.issn.1006-5253.2023.02.003

Abstract
Figure/Table
References (0)
Related Citation (4)

Download: PDF (8813 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Guide

Abstract Objective To calculate the median survival time and survival rate of patients with early-stage non-small cell lung cancer (NSCLC), and analyze the survival difference of patients with different clinical characteristics after postoperative adjuvant chemotherapy, so as to provide a basis for doctors to screen patients with possible survival benefit of postoperative adjuvant chemotherapy.Methods The data of early-stage NSCLC patients undergoing surgical treatment were extracted from SEER database. Propensity score matching (PSM) was used to control confounding factors to obtain the postoperative adjuvant chemotherapy group and the control group. The main clinical characteristics were selected to test the interaction between these clinical characteristics and postoperative adjuvant chemotherapy. Kaplan-meier method was used to compare the median survival time, 3-year survival rate and 5-year survival rate of the adjuvant chemotherapy group and the control group with different clinical characteristics.Results There were 25 791 patients with early stage NSCLC who underwent surgical treatment. The propensity score model included 11 confounding factors, and 3 336 pairs of patient samples were obtained after matching, with good balance between groups. The interaction between postoperative adjuvant chemotherapy and TNM stage, N stage, histological type, differentiation degree, and age had statistical significance on the survival of patients(P<0.05). The clinical characteristics of patients with postoperative adjuvant chemotherapy survival benefit were: stage-II, stage-T2, stage-T3, stage-N1, poorly-differentiated tumor, histological type of squamous cell carcinoma, age＞60 years old. The median survival time of patients with survival benefit wassignificantly prolonged, and the 3-year and 5-year survival rates were higher than those of the control group(P<0.05). The patients with stage-II, stage-N1 and histological type squamous cell carcinoma had the most significant benefit: the HR of the postoperative adjuvant chemotherapy group with stage-II was 0.70(95%CI: 0.63-0.77); the HR of the postoperative adjuvant chemotherapy group with stage-N1 was 0.68(95%CI:0.59-0.77); the HR of the postoperative adjuvant chemotherapy group with squamous cell carcinoma was 0.68(95%CI:0.59-0.78). The 3-year and 5-year survival rates of stage-IA and well-differentiated patients in the chemotherapy group were lower than those in the control group. The HR of the postoperative adjuvant chemotherapy group with stage-IA was 2.33(95%CI:1.58-3.42); the HR of the postoperative adjuvant chemotherapy group with well-differentation was 1.76(95%CI:1.27-2.42).Conclusion Postoperative adjuvant chemotherapy can greatly improve the lung cancer-specific survival rate of patients with high TNM staging, poorly differentiation and pathological type of squamous cell carcinoma, so postoperative adjuvant chemotherapy is recommended; elderly patients should be careful to use postoperative adjuvant chemotherapy after strict evaluation of various indicators; postoperative adjuvant chemotherapy has adverse effects on the survival of stage-IA and well-differentiated patients. Doctors should be wary of overtreatment in clinical therapeutics.

Key words： non-small cell lung cancer postoperative adjuvant chemotherapy propensity score survival rate

Received: 26 September 2022

PACS:

Fund:

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Xu Lingyan
	Li Qianni
	Li Jian
	Liu Meina

Cite this article:

Xu Lingyan,Li Qianni,Li Jian, et al. Survival benefit analysis of postoperative adjuvant chemotherapy for early-stage NSCLC[J]. journal1, 2023, 30(2): 93-100.

URL:

http://manu58.magtech.com.cn/Jwk_zgyytj/EN/10.3969/j.issn.1006-5253.2023.02.003 OR http://manu58.magtech.com.cn/Jwk_zgyytj/EN/Y2023/V30/I2/93

［1］赫捷，李霓，陈万青，等．中国肺癌筛查与早诊早治指南：2021，北京［J］．中国肿瘤，2021，30(2)：81-111．DOI:10.11735/j.issn.1004-0242.2021.02.A001.

［2］SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2021［J］. CA Cancer J Clin, 2021, 71(1):7-33. DOI:10.3322/caac.21654.

［3］GOLDSTRAW P, CHANSKY K, CROWLEY J, et al. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer［J］. J Thorac Oncol, 2016, 11(1):39-51. DOI:10.1016/j.jtho.2015.09.009.

［4］WU Y L, TSUBOI M, HE J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer［J］. N Engl J Med, 2020, 383(18):1711-1723. DOI:10.1056/NEJMoa2027071.

［5］中国抗癌协会肺癌专业委员会，中华医学会肿瘤学分会肺癌学组，中国胸部肿瘤研究协作组. Ⅰ～ⅢB期非小细胞肺癌完全切除术后辅助治疗指南：2021版［J］. 中华医学杂志，2021，101（16）：1132-1142. DOI: 10.3760/cma.j.cn112137-20210210-00406.

［6］WHITE A, KUCUKAK S, LEE D N, et al. Chemotherapy and surgical resection for N1 positive non-small cell lung cancer: Better than expected outcomes［J］. Semin Thorac Cardiovasc Surg, 2021, 33(4):1105-1111. DOI:10.1053/j.semtcvs.2021.01.012.

［7］LUO J Z, HUANG Q Y, WANG R, et al. Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB［J］. J Cancer Res Clin Oncol, 2016, 142(9):2031-2040. DOI:10.1007/s00432-016-2192-6.

［8］中华医学会肿瘤学分会，中华医学会杂志社.中华医学会肿瘤学分会肺癌临床诊疗指南：2021版［J］.中华肿瘤杂志，2021，43（6）：591-621. DOI：10.3760/cma.j.cn112152-20210207-00118.

［9］彭胜祖，李晓，王云，等．术后辅助化疗对I期非小细胞肺癌无瘤生存时间的影响［J］．中国肺癌杂志，2017，20(7)：485-489．DOI:10.3779/j.issn.1009-3419.2017.07.10.

［10］ZHANG P, DUAN J C, BAI H, et al. Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer［J］. Thorac Cancer, 2021, 12(1):30-39. DOI:10.1111/1759-7714.13685.